Loading
Life sciences · Journal article
The Faseb Journal · September 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Diabetes mellitus (DM) and hypothyroidism (HypoT) are common endocrine–metabolic disorders that frequently coexist, forming a biologically complex comorbidity rather than a simple clinical overlap. Increasing evidence suggests that DM–HypoT comorbidity arises from reciprocal disturbances in insulin action, thyroid hormone signaling, immune–inflammatory regulation, and cellular energy sensing. Thyroid hormone deficiency may impair glucose utilization, promote insulin resistance, and aggravate metabolic stress, whereas diabetes‐associated hyperinsulinemia, oxidative stress, and chronic inflammation may disrupt hypothalamic–pituitary–thyroid axis activity, thyroid hormone synthesis, and peripheral hormone activation. Subclinical hypothyroidism may represent an early biochemical phenotype within this interaction and often intersects with obesity and metabolic syndrome. Additional biological nodes, including gut dysbiosis, micronutrient imbalance, AGE–RAGE signaling, and tissue‐specific mitochondrial dysfunction, may further amplify endocrine–metabolic dysregulation. However, causal hierarchy, tissue specificity, phenotype heterogeneity, and responsive patient subgroups remain incompletely defined. This review synthesizes current epidemiological and mechanistic evidence and proposes an integrated pancreatic islet–immune–gut–thyroid axis framework to support mechanism‐informed risk stratification, biomarker development, and translational intervention strategies for DM–HypoT comorbidity.